---
title: "ChemPartner's subsidiary plans to invest 58 million yuan in an industrial fund focusing on innovative drugs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255775391.md"
description: "ChemPartner's wholly-owned subsidiary Beihai ChemPartner has signed an agreement with Shenzhen Investment Holdings Donghai Investment and other partners to jointly invest in the establishment of Shenzhen Luohu Donghai ChemPartner Pharmaceutical Industry Partnership, with a total subscription amount of 200 million yuan, of which Beihai ChemPartner contributes 58 million yuan, accounting for 29%. The partnership will focus on investing in innovative drugs and medical devices, aiming to enhance the company's capital operation capabilities and competitiveness"
datetime: "2025-09-03T11:31:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255775391.md)
  - [en](https://longbridge.com/en/news/255775391.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255775391.md)
---

# ChemPartner's subsidiary plans to invest 58 million yuan in an industrial fund focusing on innovative drugs

According to the Zhitong Finance APP, ChemPartner (300149.SZ) announced that its wholly-owned subsidiary Beihai Ruizhi Venture Capital Co., Ltd. (referred to as "Beihai Ruizhi") has signed a partnership agreement with the professional investment institution Shenzhen Donghai Investment Co., Ltd. (referred to as "Donghai Investment") and other limited partners, Shenzhen Luohu Industrial Promotion Partnership (Limited Partnership), to jointly invest in the establishment of Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership (Limited Partnership) (tentative name). The total capital contribution by all partners is set at 200 million yuan, of which Beihai Ruizhi, as a limited partner, will contribute 58 million yuan, accounting for 29% of the total subscribed capital.

The partnership intends to invest in the healthcare industry, focusing on innovative drugs and medical devices, with a key emphasis on innovative drugs. The announcement stated that the subsidiary's investment in this fund will help the company enhance its capital operation capabilities by leveraging the investment capabilities, funding advantages, and risk control abilities of professional investment institutions, empower the synergy of the innovative drug industry, and achieve investment returns, thereby consolidating and improving the company's competitiveness

### Related Stocks

- [300149.CN](https://longbridge.com/en/quote/300149.CN.md)

## Related News & Research

- [Key facts: Li Auto L9 uses FlexNoC/Magillem for 2,560 TOPS; shares fall](https://longbridge.com/en/news/286979573.md)
- [Pure Tungsten Completes Merger with GB Innovation Co., Ltd., Advancing Toward Near-Term Production and Planned Public Listing](https://longbridge.com/en/news/286944364.md)
- [Kioxia weighs plan to float ADSs against conditions](https://longbridge.com/en/news/286796988.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [02:50 ETPowerbox wprowadza na rynek serię wytrzymałych przetworników DC/DC do zastosowań w sektorze obronnym](https://longbridge.com/en/news/286867266.md)